Risk factors for chronic rejection - A clinical perspective

Transplant Immunology

Volumn 6, Issue 1, 1998, Pages 1-11

  Matas, Arthur J ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BOX 328 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AZATHIOPRINE; CYCLOSPORIN; HLA ANTIGEN;

CHILD CARE; FLOW CYTOMETRY; GLOMERULUS FILTRATION; GRAFT REJECTION; HLA MATCHING; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 0032029494     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(98)80029-4     Document Type: Article

References (94)

1. Schweitzer EJ, Matas AJ, Gillingham K, et al. Cause of renal allograft loss: progress in the '80s, challenges for the '90s. Ann Surg. 214:1991;679-688.
2. Burke BA, Chavers BM, Gillingham KJ, et al. Chronic renal allograft rejection in the first 6 months posttransplant. Transplantation. 60:1995;1413-1417.
3. Matas AJ. Chronic rejection in renal transplant recipients - risk factors and correlates. Clin Transplantation. 8:1994;332-336.
4. Hostetter TH, Olson IL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentialy adverse response to renal ablation. Am J Physiol. 241:1981;F85-93.
5. Brenner BM, Cohen RA, Milford EL. In renal transplantation, one size may not fit all. J Am Soc Nephrol. 3:1992;162-169.
6. Terasaki PI, Koyama H, Cecka IM, Gjertson DW. The hyperfiltration hypothesis in human renal transplantation. Transplantation. 57:1994;1450-1454.
7. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation. 55:1993;993-995.
8. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 55:1993;752-757.
9. Laine J, Holmberg C, Hayry P. Chronic rejection and late renal allograft dysfunction. Pediatr Nephrol. 10:1996;221-229.
10. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation. 59:1995;313-318.
11. Paul LC, Murallidharan J, Benediktsson H. Immunological and hemodynamic mechanisms in chronic renal allograft rejection. Transplant Immunol. 4:1996;39-42.
12. Paul LC. Functional and histologic characteristics of chronic renal allograft rejection. Clin Transplantation. 8:1994;319-323.
13. Hayry P, Mennanser A, Yilmaz J, et al. Towards understanding the pathophysiology of chronic rejection. Clin Invest. 70:1992;780-790.
14. Vianello A, Modena F. Pros and cons of the hyperfitration theory in human renal transplantation. [Letter of the editor] Transplantation. 59:1995;1504-1505.
15. Spital A, Kokmen T. Health insurance for kidney donors: how easy is it do obtain? Transplantation. 62:1996;1356-1358.
16. Kasiske BL, Kalil RSN, Lee HS, Rao V. Histopathologic findings associated with a chronic, progressive decline in renal alograft function. Kidney Int. 40:1991;514-524.
17. Chertow BM, Milford EL, Mackenzie HS, Brenner BM. Antigen-independent determinants of cadaveric kidney transplants failure. J Am Med Assoc. 276:1996;1732-1736.
18. Troppman C, Gillingham K, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation - a multivariate analysis. Transplantation. 59:1995;962-968.
19. Troppmann C, Almond PS, Escobar FS, et al. Donor age and cause of death affect cadaver renal allograft outcome. Transplant Proc. 23:1991;1365-1366.
20. Kerr SR, Johnson EM, Gillingham KJ, Matas AJ. Living donors (LD's) age τ55; to use or not to use. Presented at the Sixteenth Annual American Society of Transplant Physicians. May, 1997.
21. Cecka JM. Early rejection: determining the fate of renal transplants. Transplant Proc. 23:1991;1263-1264.
22. Gulanikar AC, MacDonald AS, Sungertekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation. 53:1992;323-328.
23. Ferguson RM, Henry M, Elkhammas EA, Tesi RJ. Acute rejection episodes-best predictor of long-term primary cadaveric renal transplant survival. [Abstract] American Society of Transplant Surgeons, 18th Annual Scientific Meeting. 1992;83. Chicago.
24. 12. Transplantation. 57:1994;857-859.
25. Matas AJ, Gillingham KJ, Sutherland DER. Half-life and risk factors for kidney transplant outcome - importance of death with function. Transplantation. 55:1993;757-760.
26. Lindholm A, Lundgren G, Albrechtsen D, et al. Differential effects of peritransplant variables on short- and predicted long-term outcome in cyclosporine-treated recipients of cadaveric renal allografts. Transplant Proc. 22:1990;1429-1430.
27. Lindholm A, Ohlman S, Albrechtsen D, Tulveson, Persson H, Persson NH. The impact of acute ejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by three cyclosporine regimens. Transplantation. 56:1993;307-315.
28. Knechtle SJ, Heisey DM, Pirsch JD, D'Alessandro AM, Kalayoglu M, Sollinger HW. Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. Surgery. 120:1996;719-724.
29. Leggat JE Jr, Ojo AO, Leichtman AB, Port FK, Wolfe RA, Turenne MN, Held PJ. Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodes. Transplantation. 63:1997;1268-1272.
30. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation. 62:1996;1235-1241.
31. Tejani A, Cortes L, Stablein D. Clinical correlates of chronic rejection in pediatric renal transplantation: a report of the North American Renal Transplant Cooperative Study. Transplantation. 61:1996;1054-1058.
32. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. Transplant Proc. 29:1997;73-76.
33. Chavers BM, Mauer M, Gillingham KF, Matas AJ. Histology of acute rejection (AR) impacts renal allograft survival (GS) in patients (pts) with a single rejection episode (SRE). J Am Soc Nephrol. 6:1995;1076.
34. Van Saase JLCM, Van der Woude FJ, Thorogood J, et al. The relation between acute vascular interstital renal allograft rejection and subsequent chronic rejection. Transplantation. 59:1995;1280-1285.
35. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int. 49:1996;518-524.
36. Cosio FG, Pelletier RP, Falkenhain ME, et al. Impact of acute rejection and early allograft function on renal allograft survival. Transplantation. 53:1997;1611-1615.
37. Vereerstraeten P, Abramowicz D, De Pauw L, Kinnaert P. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation. 63:1997;1739-1743.
38. Zantvoort FA, D'Amaro J, Persijn GG, et al. The impact of HLA-A matching on long-term survival of renal allografts. Transplantation. 61:1996;841-844.
39. Pirsch JD, Ploeg RI, Gange S, et al. Determinants of graft survival after renal transplantation. Transplantation. 61:1996;1581-1586.
40. Isoniemi H, Taskine E, Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation. 58:1994;1195-1198.
41. Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation. 57:1994;68-72.
42. Cecka JM, Terasaki PI. The UNOS scientific renal transplant registry. Terasaki PI, Cecka JM. Clinical Transplants. 1-18:1994;UCLA Tissue Typing Laboratory, Los Angeles CA.
43. Guyot C, Nguyen JM, Cochat P, et al. Risk factors for chronic rejection in pediatric renal allograft recipients. Pediatr nephrol. 10:1996;723-727.
44. Birk PE, Matas AJ, Gillingham KR, et al. Risk factors for chronic rejection in pediatric renal transplant recipients - a single-center experience. Pediatr Nephrol. 11:1997;395-398.
45. Donaldson P, Underhill J, Doherty D, et al. Influence of human leukocyte antigen matching on liver allograft survival and rejection: the dualistic effect. Hepatology. 17:1993;1008-1015.
46. O'Grady JG, Sutherland S, Harvey F, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet. 6:1988;302-305.
47. Candinas D, Gunson BK, Nightingale P, Hubscher S, McMaster P, Neuberger JM. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet. 346:1995;1117-1121.
48. Arnold JC, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJM, Williams R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology. 16:1992;285-292.
49. Manez R, White LT, Linden P, et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation. 55:1993;1067-1071.
50. Lautenschlager I, Hockerstedt K, Jalanko H, et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology. 25:1997;190-194.
51. Freese DK, Snover DC, Sharp HL, Gross CR, Savick SK, Payne WD. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology. 13:1991;882-891.
52. Wiesner RH, Ludwig J, Vanlloek B, Krom RAF. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology. 14:1991;721-729.
53. Devlin JJ, O'Grady JG, Tan KC, Caine RY, Williams R. Ethnic variations in patient and graft survival after liver transplantation. Transplantation. 56:1993;1381-1384.
54. Scott JP, Higenbottam TW, Sharples L, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation. 51:1991;813-817.
55. Sharples LD, Tamm M, McNeil K, Higenbottam TW, Stewart S, Wallwork J. Development of bronchiolitis obliterans syndrom in recipients of heart-lung transplantation - early risk factors. Transplantation. 61:1996;560-566.
56. Paradis IL, Yousem SA, Griffith BP. Alrway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med. 4:1993;751.
57. Cerrina J, Ladurie FLR, Herve PH, et al. Role of CMV pneumonia in the development of obliterative bronchiolitis in heart-lung and double-lung transplant recipients. Transplant Int. 5:1992;S242-S245. (suppl 1).
58. Keenan RJ, Zeevi A. Immunologic consequences of transplantation. Chest Surg Clin N Am. 5:1995;107-120.
59. Keenan RJ, Lega ME, Dummer S, et al. Cytomegalvirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 51:1991;433-438.
60. Yousem SA, Dauber JA, Keenan R, Paradis IL, Zeevi A, Griffith BP. Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans? Transplantation. 52:1991;306-309.
61. Koskinen P, Lemstrom K, Mattila S, et al. Cytomegalovirus infection associated with accelerated heart allograft arteriosclerosis may impair the late function of the graft. Clin Transplantation. 10:1996;487-493.
62. Koskinen PK, Neiminen MS, Krogerus LA, et al. Cytomegalovirus infection and accelarated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant. 12:1992;724-729.
63. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc. 261:1989;3561-3566.
64. Loebe M, Schuler S, Zais O, Warnecke H, Fleck E, Hetzer R. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant. 6:1990;707-711.
65. Durham JR, Nakhleh RE, Levine A, Levine TB. Persistence of interstitial inflammation after episodes of cardiac rejection associated with systemic infection. J Heart Lung Transplant. 14:1995;774-780.
66. Paya CV, Wiesner RH, Hermans PE, et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after live transplantation. Hepatology. 16:1992;66-70.
67. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation. 49:1990;374-377.
68. Dunn J, Golden D, Van Buren CT, Lewis RM, Lawen J, Kahan BD. Causes of graft loss beyond two years in the cyclosporine era. Transplantation. 49:1990;349-353.
69. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc. XX:1988;63-69. (suppl 3).
70. Rudman LA, Gonzales MH, Borgida E. Mishandling the gift of life: noncompliance in renal transplant patients. J Appl Social Psychol. 1988;. in press.
71. DeGeest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, Vanreterghem Y. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation. 59:1995;340-347.
72. Nevins TE, Gillingham KJ, Schmidt W, Matas AJ. Natural history of medication compliance after transplant: preliminary results. May, 1996;26-29 American Society of Transplant Physicians, Dallas, TX.
73. Baldwin WM, Soulillou JP, Claas FHJ, Peyrat MA, van Es LA, van Rood JJ. Antibodies to endothelial antigens in eluates of 88 human kidneys: correlation with graft survival and presence of T- and B-cell antibodies. Transplant Proc. XIII:1981;1547-1550.
74. Mohanakumar T, Waldrep JC, Phibbs M, et al. Serological characteristics of antibodies eluted from chronically rejected human renal allografts. Transplantation. 32:1981;61-66.
75. Suciu-Foca N, Reed E, D'Agati VD, et al. Soluble HLA-antigens, anti-HLA antibodies and anti-idiotypic in the circulation of renal transplant recipients. Transplantation. 51:1991;593-601.
76. Suciu-Foca N, Reed E, Marboe C, et al. Role of anti-HLA antibodies in heart transplantation. Transplantation. 51:1991;716-724.
77. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Trasnplantation. 61:1996;566-572.
78. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Antiendothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 339:1992;1566-1570.
79. Ferry BL, Welsh KI, Dunn MJ, et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: associatin with chronic rejection. Transplant Immunol. 5:1997;17-24.
80. Abe M, Kawai T, Futatsuyama K, et al. Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation. 63:1997;1616-1619.
81. Reinsmoen NL, Hertz MI, Kubo S, Bolman RN, Matas AJ. Immune factors correlating with improved long-term graft outcome in kidney, lung, and heart transplant. Transplant Proc. 25:1993;3277-3278.
82. Reinsmoen NL, Bolman RM, Savik K, Butters K, Matas AJ, Hertz MI. Improved long-term graft outcome in lung transplant recipients who have donor antigen-specific hyporeactivity. J Heart Lung Transplant. 13:1994;30-37.
83. Reinsmoen NL, Hertz MI, Kubo SH, Bolman RM, Matas AJ. Reduced incidence of chronic rejection in cyclosporine-treated solid organ recipients with donor antigen-specific hyporeactivity. Transplant Proc. 26:1994;2558-2559.
84. Reinsmoen NL, Matas AJ. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity. Transplantation. 55:1993;1017-1023.
85. Reinsmoen NL, Troppman C, Matas AJ. Risk factors for chronic rejection: influence of donor antigen-specific responder status. Submitted.
86. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, Chimerism, and graft acceptance. Lancet. 339:1992;1579-1582.
87. Starzl TE, Demetris AJ, Truco M, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology. 17:1993;1127-1152.
88. Starzl TE, Demetris AJ, Murase N, et al. The lost chord: microchimerism and allograft survival. Immunol Today. 17:1996;577-584.
89. Schlitt HJ, Hundrieser J, Ringe B, Pichlmayr R. Donor-type microchimerism associated with graft rejection eight years after liver transplantation. E Engl J Med. 328:1994;646-647.
90. Suberbielle C, Caillat-Zucman S, Legendre C, et al. Peripheral Microchimerism in long-term cadaveric-kidney allograft recipients. Lancet. 343:1994;1468-1469.
91. Sivasia KSR, Alevy Y, Duffy B, et al. Peripheral blood microchimerism in human liver and renal transplant recipients. Transplantation. 64:1997;427-432.
92. Reinsmoen NL, McSherry C, Jackson A, et al. Donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimersm as predictors of a chronic rejection-free state in lung and heart recipients. 15th Annual Scientific Meeting of the American Society of Transplant Physicians. May, 1997;. Chicago, IL.
93. Jackson A, McSherry C, Kubo S, Ormaza S, Reinsmoen NL. Peripheral Blood allogeneic microchimerism 2 years postransplant is associated with a lower incidence of coronary artery disease in heart recipients. 22nd Annual Meeting of the American Society of Histocompatibility and Immunogenetics. October, 1996;. San Diego, CA.
94. Hunsicker LG, Bennett LE. Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int. 48:1995;S120-S123. (suppl 52).